Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.
Pediatric Nutrition Woes Overshadow Robust Medical Device Growth
Abbott's stock decline reflects persistent struggles in its pediatric nutrition segment, largely due to the 2022 infant formula recall. This weakness is obscuring strong performance in its medical device and diagnostics divisions, creating a mixed picture for investors.
Investors should monitor Abbott's FreeStyle Libre growth to see if it can offset the continued drag from nutrition.
Key Takeaways
- 1Abbott's nutrition division is struggling to regain pre-2022 market share levels following significant supply chain disruptions and recalls in its infant formula business.
- 2The medical device segment remains a bright spot, anchored by the FreeStyle Libre continuous glucose monitor, which continues to see robust global demand.
- 3Despite a diversified revenue stream, the company's EPS outlook is being pressured by increased marketing and legal costs associated with its nutrition products.
- 4Mainstream investors are shifting focus toward pure-play medical technology competitors as Abbott's diversified model currently faces an 'under-recovery' discount.
Abbott Laboratories (ABT) is facing significant headwinds as its pediatric nutrition segment continues to weigh on overall financial performance, overshadowing gains in its medical device and diagnostics divisions. This slump is primarily rooted in the lingering aftermath of the 2022 infant formula recall and the subsequent closure of its Sturgis facility, which has allowed competitors like Reckitt Benckiser to gain market share. While Abbott has restored much of its production capacity, the recovery of consumer trust and shelf space remains a slow, capital-intensive process. From a broader sector perspective, this highlights a divergence within the healthcare conglomerate: while the medical device segment thrives—driven by the FreeStyle Libre glucose monitor and recovery in elective surgeries—the nutrition business remains a multi-year recovery story. Investors should view this as a transitionary phase where the high-margin med-tech business is being offset by lower-margin specialty retail recovery. Forward-looking, the key metric for investors will be whether the anticipated double-digit growth in medical devices can accelerate enough to compensate for the stagnation in the nutrition segment, especially as birth rates trend lower in key markets.